Please ensure Javascript is enabled for purposes of website accessibility
Home / News / KC Daily Record / Myriad seeks to block competing DNA test

Myriad seeks to block competing DNA test

Myriad has invested more than $500 million to create diagnostic test

Following a mixed U.S. Supreme Court ruling on patenting human genes, Myriad Genetics Inc. is looking for a ruling protecting its patents on "breast and ovarian cancer tests."

Leave a Reply

Your email address will not be published. Required fields are marked *

*